Eurand N.V. (NASDAQ: EURX) today announced data from a Phase II/III clinical study demonstrating that ZENPEP (pancrelipase) Delayed-Release Capsules significantly ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE